Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
29.81
-0.18 (-0.60%)
At close: Sep 4, 2026, 4:00 PM EDT
30.00
+0.19 (0.64%)
After-hours: Sep 4, 2026, 7:55 PM EDT
Stoke Therapeutics Employees
Stoke Therapeutics had 170 employees as of December 31, 2025. The number of employees increased by 42 or 32.81% compared to the previous year.
Employees
170
Change (1Y)
42
Growth (1Y)
32.81%
Revenue / Employee
$162,282
Profits / Employee
-$1,222,959
Market Cap
1.92B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 170 | 42 | 32.81% |
| Dec 31, 2024 | 128 | 18 | 16.36% |
| Dec 31, 2023 | 110 | -7 | -5.98% |
| Dec 31, 2022 | 117 | 15 | 14.71% |
| Dec 31, 2021 | 102 | 23 | 29.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Agios Pharmaceuticals | 540 |
| Immunocore Holdings | 524 |
| Maravai LifeSciences Holdings | 415 |
| Vir Biotechnology | 367 |
| Xencor | 260 |
| Kardigan | 241 |
| Lakefront Biotherapeutics NV | 196 |
STOK News
- 4 days ago - Stoke Therapeutics, Biogen present long-term data on Zorevunersen - TheFly
- 4 days ago - Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Business Wire
- 5 days ago - Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Business Wire
- 6 days ago - Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate - TheFly
- 17 days ago - Stoke Therapeutics reinstated with an Overweight at JPMorgan - TheFly
- 20 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 26 days ago - Stoke Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 4 weeks ago - Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Business Wire